ICICI Securities upgrades Divi's Laboratories, Pfizer and Jubilant Pharma to BUY
ICICI Securities remain positive on the pharmaceutical sector considering high possibility of growth revival in India formulations on low base of FY21, stable pricing in US generics and sustenance of cost control initiatives seen during FY21 due to pandemic, albeit partially over long term.
ICICI Securities remain positive on the pharmaceutical sector considering high possibility of growth revival in India formulations on low base of FY21, stable pricing in US generics and sustenance of cost control initiatives seen during FY21 due to pandemic, albeit partially over long term. Hence, FY22E EBITDA margin would likely be lower than FY21 with resumption of some S,G&A expenses (travelling, marketing etc.) but would still be higher than FY20 levels. ICICI Securities believes underperformance of the sector in the last few months has factored in this concern. ICICI Securities maintains a positive stance on the Pharma sector. Considering the recent stock price movement, ICICI Securities have upgraded Divi’s, Pfizer and Jubilant Pharmo to BUY from Add.
See Zee Business Live TV Streaming Below:
ICICI Securities have assumed an increase in SG&A expenses for FY22E over FY20 levels and any incremental savings will provide an upside. ICICI Securities prefer companies with a strong India business, complex generics pipeline for the US and improving return ratios.
India growth to revive in FY22E, US to steadily improve:
IPM reported a muted growth of 1.9% in MAT Feb’21 (as per AIOCD-AWACS) due to lockdown impact. ICICI Securities believes 10% growth is sustainable over medium-term with 4-5% volume, 3-4 price and 2-3% new products growth, and FY22E may witness higher growth on a low base. US sales have stabilised over past few quarters as price erosion has come down and new launches continue. ICICI Securities expect US sales to gradually improve hereon for companies led by new approvals and complex/limited competition products. Resumption of USFDA inspections would help companies in resolving existing issues but could be a concern for other plants, if found non-compliant.
Savings in S,G&A expenses partially sustainable:
The companies witnessed significant cost savings in India & other branded generic businesses during the pandemic as travelling and promotional costs were restricted. These costs are gradually increasing as witnessed during Q3FY21 and we expect normalisation in FY22E. We expect a hybrid model (digital+physical) to be the norm in the future which will help in sustaining some of the cost benefits. ICICI Securities have assumed S,G&A to be higher in FY22E over FY20 and any incremental savings would provide upside.
Pharma Top picks:
Cipla (BUY):
Focus on India & branded generic segments along with profitability improvement and high growth visibility
Alkem Labs (BUY):
Solid India business, improving margin trajectory, consistent track record of growth outperformance and attractive valuations
Abbott India (BUY):
Strong growth across therapies and marquee products to continue, generate strong cash flows pushing return ratios even higher
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Retirement Planning: SIP+SWP combination; Rs 15,000 monthly SIP for 25 years and then Rs 1,52,000 monthly income for 30 years
Retirement Calculator: 40 years of age, Rs 50,000 monthly expenses; what should be retirement corpus and monthly investment
SBI 444-day FD vs Union Bank of India 333-day FD: Know maturity amount on Rs 4 lakh and Rs 8 lakh investments for general and senior citizens
EPF vs SIP vs PPF Calculator: Rs 12,000 monthly investment for 30 years; which can create highest retirement corpus
Home loan EMI vs Mutual Fund SIP Calculator: Rs 70 lakh home loan EMI for 20 years or SIP equal to EMI for 10 years; which can be easier route to buy home; know maths
02:17 PM IST